Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F17%3A00074352" target="_blank" >RIV/65269705:_____/17:00074352 - isvavai.cz</a>
Result on the web
<a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.026714" target="_blank" >https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.026714</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1161/CIRCULATIONAHA.116.026714" target="_blank" >10.1161/CIRCULATIONAHA.116.026714</a>
Alternative languages
Result language
angličtina
Original language name
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
Original language description
Atrial fibrillation (AF) and valvular heart disease frequently coexist and independently increase mortality.1 Bioprosthetic valve implantation (surgical or transcatheter) is a common, increasingly utilized treatment for valvular heart disease.2 Patients with AF and bioprosthetic valves require anticoagulation to prevent thromboembolic events. Non-vitamin K oral anticoagulants are safe and efficacious alternatives to vitamin K antagonists for anticoagulation in AF. However, guidelines recommend against using non-vitamin K oral anticoagulants in patients with bioprosthetic valves, citing a lack of supporting data. Only 1 of the first 3 warfarin-controlled pivotal non-vitamin K oral anticoagulants trials in AF included patients with bioprosthetic valves (n>80).3 The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation Thrombolysis in Myocardial Infarction 48), which compared edoxaban (a direct oral factor Xa inhibitor) to warfarin in patients with AF,4 did not exclude patients with bioprosthetic valves, thus providing an opportunity to analyze this high-risk subgroup.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Circulation
ISSN
0009-7322
e-ISSN
—
Volume of the periodical
135
Issue of the periodical within the volume
13
Country of publishing house
US - UNITED STATES
Number of pages
3
Pages from-to
1273-1275
UT code for WoS article
000397387200020
EID of the result in the Scopus database
—